Steminent Biotherapeutics Inc. (TPEX:7729)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
81.50
-2.00 (-2.40%)
Mar 24, 2026, 1:52 PM CST
Market Cap5.56B +336.4%
Revenue (ttm)n/a
Net Income-156.75M
EPS-2.79
Shares Out66.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume273,541
Average Volume559,393
Open84.00
Previous Close83.50
Day's Range81.10 - 85.20
52-Week Range15.25 - 95.60
Beta0.41
RSI48.56
Earnings DateApr 22, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 47
Stock Exchange Taipei Exchange
Ticker Symbol 7729
Full Company Profile

Financial Performance

Financial Statements